Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes

Prior treatment

• Concurrent malignant tumors of other organs, which can be enrolled if previously cured;
• Concomitant hematologic disorders;

Other illness

• Extramedullary disease involvement；
• Hypersensitivity to any study drugs；
• Severe cardiac disease, including congestive heart failure, myocardial infarction, and cardiac insufficiency;
• Active tuberculosis or HIV infection;

Other

• Clinically significant hepatic/renal dysfunction exceeding inclusion thresholds；
• Pregnancy or lactation;
• Inability to comply with protocol requirements;
• Concurrently participating in other clinical studies.

• Newly diagnosed MDS confirmed by morphological and immunophenotypic analysis of bone marrow；
• Age ≥18 years, any gender；
• Bone marrow blasts ≥10%；
• IPSS-R score \>4.5；
• ECOG performance status 0-2；
• Scheduled for allogeneic hematopoietic stem cell transplantation (allo-HSCT)；
• Adequate major organ function：
  • Cardiac: LVEF ≥50%
  • Hepatic: Bilirubin ≤1.5×ULN
  • AST/ALT ≤2.5×ULN
  • Renal: Creatinine clearance ≥60 mL/min；
• Written informed consent provided by the patient or legally authorized representative.